National Pension Service Has $187.80 Million Stock Holdings in Stryker Co. (NYSE:SYK)

National Pension Service grew its holdings in shares of Stryker Co. (NYSE:SYK) by 2.4% during the fourth quarter, Holdings Channel reports. The firm owned 627,139 shares of the medical technology company’s stock after purchasing an additional 14,830 shares during the period. National Pension Service’s holdings in Stryker were worth $187,803,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SYK. Lindbrook Capital LLC lifted its stake in shares of Stryker by 5.1% in the third quarter. Lindbrook Capital LLC now owns 1,007 shares of the medical technology company’s stock worth $275,000 after buying an additional 49 shares during the last quarter. Verdence Capital Advisors LLC lifted its position in Stryker by 9.2% during the 3rd quarter. Verdence Capital Advisors LLC now owns 1,017 shares of the medical technology company’s stock worth $278,000 after acquiring an additional 86 shares during the last quarter. Brighton Jones LLC grew its position in shares of Stryker by 4.8% in the third quarter. Brighton Jones LLC now owns 3,676 shares of the medical technology company’s stock valued at $1,005,000 after purchasing an additional 170 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Stryker by 16.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 95,382 shares of the medical technology company’s stock worth $26,066,000 after purchasing an additional 13,307 shares during the period. Finally, River Street Advisors LLC lifted its holdings in shares of Stryker by 6.9% during the third quarter. River Street Advisors LLC now owns 1,586 shares of the medical technology company’s stock worth $433,000 after buying an additional 102 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock traded up $1.82 during trading on Thursday, hitting $331.10. 368,365 shares of the stock were exchanged, compared to its average volume of 1,320,488. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The stock has a market capitalization of $126.13 billion, a price-to-earnings ratio of 37.74, a price-to-earnings-growth ratio of 2.54 and a beta of 0.91. The company has a fifty day moving average price of $346.05 and a 200-day moving average price of $318.84. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The business had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. During the same period in the previous year, the firm earned $2.14 EPS. The firm’s revenue was up 9.7% compared to the same quarter last year. As a group, equities analysts predict that Stryker Co. will post 11.94 EPS for the current fiscal year.

Analyst Ratings Changes

SYK has been the topic of a number of research reports. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and boosted their target price for the stock from $315.00 to $360.00 in a research report on Wednesday, January 31st. Evercore ISI increased their price objective on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. UBS Group upped their target price on shares of Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a research report on Wednesday, May 1st. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Finally, BTIG Research upped their target price on shares of Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $365.94.

Insider Transactions at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.